CHANDLER, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX: IXS.V), a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, today announced that it has appointed Angela Giannoccaro as its Chief Financial Officer. Ms. Giannoccaro assumed her role on October 17th, 2011. She will oversee InNexus non-research and development administrative functions in addition to her financial management responsibilities.
Ms. Giannoccaro is a public accountant with both her bachelor's and master's in Accountancy. “Angela is experienced and hardworking, and given her knowledge of complex operations, she’ll be a great asset to InNexus. Join me in welcoming her aboard,” said Jeff Morhet, Chief Executive of InNexus.
The company also announced today that it has priced the incentive stock options announced on September 16 at $.10 per common share instead of the $.05 that was listed in the previous press release. The granted incentive stock options are to purchase an aggregate of 1,068,683 common shares without par value in the capital of the Company to certain persons who are a director, officer, employee or consultant of the Company. The stock options will be exercisable for a period of five years expiring on August 27, 2016, at a price of $0.10 per common share.
The Options will vest equally on a quarterly basis, over a period of 18 months, or will vest immediately in the event of a change of control of the Company or (at the discretion of the Board of Directors) takeover bid, subject to the approval of the TSX Venture Exchange.
The granting of the foregoing incentive stock options is subject to acceptance by the TSX Venture Exchange.
About InNexus Biotechnology
InNexus is developing commercial opportunities based on the expanding field of monoclonal antibodies utilizing its proprietary technologies in three focus areas: ophthalmology, dermatology and oncology. InNexus is listed on the TSX Venture Exchange (TSX.V: IXS).
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.